Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Intern Med ; 59(21): 2679-2685, 2020 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-32669489

RESUMEN

Objective A low-normal albumin level is associated with a high risk of cardiovascular disease and mortality in the general population. However, the relationship between the serum albumin level and the future decline in the kidney function is unclear. We evaluated the effect of the serum albumin level on the decline in the kidney function in the general population. Methods The data used were from 11,000 participants in a voluntary health checkup program conducted between 1998 and 2006 in Japan. The primary outcome for the kidney function was a difference in the estimated glomerular filtration rate (ΔeGFR) of≥3 mL/min/1.73 m2/year. The association of the risk of a decreased kidney function with the albumin level was determined using a logistic regression analysis. We fit separate multivariable logistic regressions for the serum albumin levels (g/dL) as a continuous variable and as categorical data, classified as ≤4.3 (n=2,530), 4.4-4.6 (n=5,427), and≥4.7 (n=3,043). Results Of the 11,000 participants, 346 had a ΔeGFR/year of≥3. Compared with the participants with albumin levels of≥4.7 g/dL, the risk of a decline in the kidney function was higher not only in those with albumin levels of ≤4.3 g/dL [adjusted odds ratio (OR) =2.10, 95% confidence interval (CI): 1.20-2.93] but also in those with levels of 4.4-4.6 g/dL (adjusted OR=1.53, 95% CI: 1.14-2.05). Conclusion A decreased albumin level is an independent risk factor for a rapid decline in the kidney function, even within the normal range.


Asunto(s)
Tasa de Filtración Glomerular , Valor Predictivo de las Pruebas , Insuficiencia Renal/sangre , Insuficiencia Renal/diagnóstico , Insuficiencia Renal/fisiopatología , Medición de Riesgo/métodos , Albúmina Sérica/análisis , Adulto , Anciano , Estudios de Cohortes , Femenino , Humanos , Japón/epidemiología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Valores de Referencia , Insuficiencia Renal/epidemiología , Estudios Retrospectivos , Factores de Riesgo
2.
Oxid Med Cell Longev ; 2018: 9714710, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30116501

RESUMEN

Xanthine oxidase (XO), an isoform of xanthine oxidoreductase (XOR), is thought to increase the cardiovascular burden among chronic kidney disease (CKD) patients via oxidative radical production. Plasma XOR redox, which is characterized by the ratio of XO to total XOR, changes under different oxidative conditions associated with kidney dysfunction. However, the relationship between plasma XOR redox and oxidative stress (OS) is unclear. Thus, we aimed to clarify whether OS is related to XOR redox. We used the redox state of human serum albumin (HSA) as a marker to investigate the status of OS in CKD patients. HSA is composed of human mercaptoalbumin (HMA), which possesses not oxidized cysteine residues, reversibly oxidized human nonmercaptoalbumin-1 (HNA-1), and strongly oxidized human nonmercaptoalbumin-2 (HNA-2). The subjects included 13 nondialysis patients (7 males and 6 females) with varying degrees of kidney function. We found that ƒ(HMA) was negatively (R = -0.692, P = 0.0071) and ƒ(HNA-1) was positively (R = 0.703, P = 0.0058) correlated with plasma XO/XOR. ƒ(HNA-2) showed no correlation with XO/XOR (R = 0.146, P = 0.6412), indicating that plasma XOR redox is not related to the irreversible oxidation of HSA. In conclusion, plasma XOR redox is closely related to HSA redox, particularly reversible oxidation of HSA.


Asunto(s)
Estrés Oxidativo/genética , Insuficiencia Renal Crónica/genética , Insuficiencia Renal Crónica/metabolismo , Xantina Deshidrogenasa/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad
5.
Clin Exp Nephrol ; 12(6): 522-6, 2008 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-18979061

RESUMEN

A 59-year-old man underwent total gastrectomy and splenectomy for gastric cancer 14 months before admission. The pathological diagnosis was neuroendocrine carcinoma of the stomach. Eight months after the operation, systemic chemotherapy with irinotecan and cisplatin was started because of multiple metastases to lymph nodes. After two courses of chemotherapy, renal function continued to decline. Renal biopsy showed acute tubular necrosis with cast formation, where needle crystallization was found. These clinicopathological findings suggested that tumor lysis syndrome was the cause of acute renal insufficiency. Moreover, diffuse, global bubbling and focal segmental spike formation were revealed by periodic acid-silver methenamine stain in the glomerular basement membrane. Electron microscopy showed an infolding of the cytoplasm of podocytes into the basal basement membrane and spotty electron-lucent areas. These ultrastructural findings, but not epimembranous deposits, corresponded with the bubbling on PAM staining. The present case was a rare case of glomerulopathy associated with podocytic infolding, which was not associated with collagen disease but with tumor lysis syndrome.


Asunto(s)
Membrana Basal Glomerular/patología , Glomerulonefritis Membranosa/patología , Podocitos/patología , Síndrome de Lisis Tumoral/patología , Membrana Basal Glomerular/ultraestructura , Humanos , Masculino , Microscopía Electrónica , Persona de Mediana Edad , Podocitos/ultraestructura
6.
Nephrol Dial Transplant ; 22(5): 1407-12, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17264097

RESUMEN

BACKGROUND: Iron supplementation is a mainstay for management of renal anaemia in patients receiving haemodialysis (HD). Although it is well known that a single intravenous iron (IVIR) administration transiently enhances oxidative stress in HD patients, the consequence of repeated IVIR administration is still unknown. This study aims to clarify the time course of changes in serum 8-hydroxy-2'-deoxyguanosine (8-OHdG), a marker of DNA oxidative injury, during a period of repeated IVIR administration in HD patients. METHODS: Twenty-seven patients (62+/-14 years and 23 males) on long-term HD participated in this study. All patients had been on HD more than 6 months and none had received a blood transfusion or iron therapy in previous 6 months. The patients were divided into three groups according to the baseline haematocrit (Ht) and serum ferritin (FTN) levels as a marker of body iron stores: IVIR group (Ht<30% and FTN<100 ng/ml; n=7); High FTN group (Ht>or=30% and FTN>or=100 ng/ml; n=11); and low FTN group (Ht>or=30% and FTN<100 ng/ml; n=9). The IVIR group patients received 40 mg of ferric saccharate i.v. after each HD session until Ht increased by 5%. Serum 8-OHdG and other parameters were prospectively monitored for 10 weeks. RESULTS: At baseline, the serum ferritin level was independently associated with 8-OHdG in a multiple regression model (total adjusted R2=0.47, P<0.01). All patients in the IVIR group achieved the target Ht level during the study. IVIR administration resulted in significant increases in 8-OHdG levels (0.22+/-0.07-0.50+/-0.16 ng/ml: baseline to 10 week) as compared with both the high FTN group (0.52+/-0.20-0.58+/-0.28 ng/ml) and the low FTN group (0.39+/-0.11-0.36+/-0.11 ng/ml) (ANOVA for repeated measures P<0.01). Additionally, serum 8-OHdG and serum ferritin changed in the same manner. CONCLUSIONS: Repeated IVIR administration for HD patients was associated with signs of increased oxidative DNA injury, as reflected by increased serum levels of 8-OHdG. As these changes were accompanied by increased serum ferritin levels, excess body iron stores might play an important role in oxidative stress.


Asunto(s)
Desoxiguanosina/análogos & derivados , Eritropoyetina/farmacología , Hierro/farmacología , Fallo Renal Crónico/terapia , Diálisis Renal , 8-Hidroxi-2'-Desoxicoguanosina , Adulto , Anciano , Anemia Ferropénica/sangre , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/etiología , Daño del ADN , Desoxiguanosina/sangre , Relación Dosis-Respuesta a Droga , Eritropoyetina/administración & dosificación , Femenino , Ferritinas/sangre , Hematócrito , Humanos , Infusiones Intravenosas , Hierro/administración & dosificación , Fallo Renal Crónico/sangre , Masculino , Persona de Mediana Edad , Estrés Oxidativo , Estudios Prospectivos , Proteínas Recombinantes , Análisis de Regresión , Diálisis Renal/efectos adversos
7.
Biochem J ; 396(1): 109-15, 2006 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-16503878

RESUMEN

The cell-surface RAGE [receptor for AGE (advanced glycation end-products)] is associated with the development of diabetic vascular complications, neurodegenerative disorders and inflammation. Recently, we isolated a human RAGE splice variant, which can work as a decoy receptor for RAGE ligands, and named it esRAGE (endogenous secretory RAGE). In the present study, we have isolated the murine equivalent of esRAGE from brain polysomal poly(A)+ (polyadenylated) RNA by RT (reverse transcription)-PCR cloning. The mRNA was generated by alternative splicing, and it encoded a 334-amino-acid protein with a signal sequence, but lacking the transmembrane domain. A transfection experiment revealed that the mRNA was actually translated as deduced to yield the secretory protein working as a decoy in AGE-induced NF-kappaB (nuclear factor kappaB) activation. RT-PCR and immunoblotting detected esRAGE mRNA and protein in the brain, lung, kidney and small intestine of wild-type mice, but not of RAGE-null mice. The esRAGE expression was increased in the kidney of diabetic wild-type mice. The present study has thus provided an animal orthologue of esRAGE for clarification of its roles in health and disease.


Asunto(s)
Receptores Inmunológicos/metabolismo , Empalme Alternativo , Secuencia de Aminoácidos , Animales , Western Blotting , Células COS , Línea Celular Tumoral , Chlorocebus aethiops , Diabetes Mellitus Experimental/metabolismo , Glioma/patología , Productos Finales de Glicación Avanzada/metabolismo , Humanos , Intestino Delgado/metabolismo , Riñón/metabolismo , Ligandos , Pulmón/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , FN-kappa B/metabolismo , Proteínas del Tejido Nervioso/análisis , Especificidad de Órganos , ARN Mensajero/genética , Ratas , Receptor para Productos Finales de Glicación Avanzada , Receptores Inmunológicos/análisis , Receptores Inmunológicos/deficiencia , Receptores Inmunológicos/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Alineación de Secuencia , Homología de Secuencia de Aminoácido , Solubilidad , Especificidad de la Especie , Relación Estructura-Actividad , Resonancia por Plasmón de Superficie , Transfección
8.
Curr Drug Targets ; 6(4): 447-52, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-16026264

RESUMEN

Vascular complications result in disabilities and short life expectancy in diabetic patients. During prolonged hyperglycemic exposure, non-enzymatically glycated protein derivatives termed advanced glycation endproducts (AGE) are formed at an accelerated rate and accumulated in blood and in tissues. Studies performed in vitro and in vivo revealed AGE and their receptor RAGE as the major accounts for vascular cell derangement characteristic of diabetes. The AGE-RAGE system would thus be considered as a candidate molecular target for overcoming diabetic vascular complications. Potential preventive and therapeutic approaches toward it include inhibition of AGE formation, breakage of preformed AGE-proteins crosslinks, blockade of AGE-RAGE interactions with RAGE competitors or antagonists and RAGE-specific signaling inhibition.


Asunto(s)
Angiopatías Diabéticas/prevención & control , Productos Finales de Glicación Avanzada/antagonistas & inhibidores , Receptores Inmunológicos/antagonistas & inhibidores , Animales , Angiopatías Diabéticas/etiología , Productos Finales de Glicación Avanzada/fisiología , Humanos , Receptor para Productos Finales de Glicación Avanzada , Receptores Inmunológicos/fisiología , Transducción de Señal
9.
Clin Exp Nephrol ; 9(2): 158-63, 2005 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-15980952

RESUMEN

BACKGROUND: Accumulating evidence suggests that oxidative stress is enhanced in patients on regular hemodialysis (HD). Iron supplementation is essential for the treatment of renal anemia, but there is a possibility that it could enhance oxidative stress by inducing the Fenton reaction. Here, we report our investigation of the relation between iron storage and DNA oxidative injury in HD patients. METHODS: The study subjects were 48 patients on regular HD (age, 62.7 +/- 12.1 years; HD duration, 67.2 +/- 62.5 months; non-diabetic/diabetic; 22:26). Patients who were positive for hepatitis C virus antibody (HCV Ab), or hepatitis B surface antigen (HBsAg), and those with inflammatory or malignant diseases were excluded. The serum 8-hydroxy-2'-deoxyguanosine (8-OHdG) level, a marker of DNA oxidative injury, was measured before the first HD session of the week in all patients, and factors associated with high serum 8-OHdG were investigated. In 9 patients with a serum ferritin level of more than 1000 ng/ml at study entry, serum 8-OHdG levels were followed up for 6 months in the absence of iron supplementation. RESULTS: Multivariate analysis showed that the serum ferritin level was a significant and independent determinant of serum 8-OHdG, and serum ferritin correlated significantly with the total dose of iron supplementation during the 6-month period of the study. In the nine patients, without iron supplementation, serum 8-OHdG levels, as well as serum ferritin, decreased significantly during follow-up. CONCLUSIONS: Our results suggest that increased iron storage may induce DNA oxidative injury in patients on regular HD, and that the serum ferritin level is a surrogate marker for this pathological condition.


Asunto(s)
Anemia/tratamiento farmacológico , Ferritinas/sangre , Hierro/efectos adversos , Fallo Renal Crónico/complicaciones , Estrés Oxidativo/efectos de los fármacos , 8-Hidroxi-2'-Desoxicoguanosina , Anciano , Anciano de 80 o más Años , Anemia/etiología , Anemia/metabolismo , Desoxiguanosina/análogos & derivados , Desoxiguanosina/sangre , Femenino , Estudios de Seguimiento , Humanos , Hierro/farmacocinética , Fallo Renal Crónico/metabolismo , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Transferrina/metabolismo
10.
Kidney Int ; 66(5): 1988-93, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15496170

RESUMEN

BACKGROUND: Cardiovascular disease is known to be the most important complication among patients with renal failure, and oxidative stress has been proposed to play a major role as the source of such complications. Human serum albumin (HSA) is composed of human mercaptoalbumin (HMA) with cysteine residues having reducing powers, of reversibly oxidized human non-mercaptoalbumin-1 (HNA-1), and strongly oxidized human non-mercaptoalbumin-2 (HNA-2). METHODS: We used the "redox state of HSA" as a marker to investigate the current status of oxidative stress in predialysis patients with renal failure. The subjects were 55 nondialysis patients (31 males and 24 females) with chronic renal diseases, and having various degrees of renal function. The subjects' redox state of HSA was determined by a high-performance liquid chromatographic (HPLC) procedure, and the results presented in terms of the ratios between HNA-total(HNA-1 + HNA-2) and HNA-2. RESULTS: The values for each fraction of HNA-total (f(HNA-total)) and f(HNA-2) were increased with a decrease of renal functions, and a significant positive correlation with serum creatinine (R= 0.529, P < 0.0001 and R= 0.618, P < 0.0001) was detected. Multiple (forward stepwise) regression analysis using f(HNA-total) and f(HNA-2) as the criterion variables was performed, and creatinine was adopted as significant explanatory variable in both equations. CONCLUSION: We found that even before dialysis, oxidative stress was enhanced in correlation with the level of renal dysfunction among patients with chronic renal failure. In the future, antioxidant strategies should become part of treatment for predialysis renal failure.


Asunto(s)
Estrés Oxidativo , Insuficiencia Renal/metabolismo , Albúmina Sérica/metabolismo , Adulto , Anciano , Biomarcadores/sangre , Cromatografía Líquida de Alta Presión , Creatinina/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oxidación-Reducción , Isoformas de Proteínas/sangre , Insuficiencia Renal/sangre , Albúmina Sérica Humana
11.
Ther Apher Dial ; 8(4): 305-12, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15274682

RESUMEN

We have established a new method of measuring translymphatic fluid absorption (TLA) using technetium-99m ((99m)Tc) human serum albumin diethylenetriamine pentaacetic acid ((99m)Tc-HSAD) that can be used commonly in clinical practice. This new method was applied in 13 continuous ambulatory peritoneal dialysis patients (11 males and two females) who had various peritoneal permeability and capacities for peritoneal transport of water. (99m)Tc-HSAD 740MBq was injected in 2 L of peritoneal dialysis fluid with 2.5% glucose, mixed well, and administered intraperitoneally. The fluid was drained extraperitoneally after 4 h and TLA was determined by the in vivo loss of (99m)Tc-HSAD. TLA was 1.41 +/- 1.11 mL/min (mean +/- SD; range, 0.27-3.69 mL/min). The estimated reduction rate by TLA in trans-peritoneally removed fluid ranged from 14.2 to 84.4%, indicating that TLA could have an extremely significant negative effect in some cases on total drainage volume. The present study, using new tracer (99m)Tc-HSAD, could confirm a large individual difference in TLA, indicating TLA as an important contributing factor for fluid-removal failure in continuous ambulatory peritoneal dialysis patients.


Asunto(s)
Líquidos Corporales/metabolismo , Diálisis Peritoneal Ambulatoria Continua , Radiofármacos , Agregado de Albúmina Marcado con Tecnecio Tc 99m , Absorción , Anciano , Agua Corporal/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Ácido Pentético , Ultrafiltración
13.
Nihon Jinzo Gakkai Shi ; 44(1): 50-3, 2002 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-11925947

RESUMEN

A 73-year-old woman with chronic renal failure developed generalized muscular weakness and pain 6 days after the start of allopurinol treatment(200 mg/day). Routine laboratory tests revealed elevated levels of serum creatine kinase, and the patient was clinically diagnosed as rhabdomyolysis, due probably to severe myositis. A high level of serum oxipurinol, the chief active metabolite of allopurinol, was also revealed. The muscular weakness was relieved in seven weeks with intermittent hemodiafiltration.


Asunto(s)
Alopurinol/efectos adversos , Fallo Renal Crónico/complicaciones , Miositis/inducido químicamente , Rabdomiólisis/inducido químicamente , Anciano , Femenino , Hemodiafiltración , Humanos , Fallo Renal Crónico/terapia , Miositis/terapia , Oxipurinol/sangre , Rabdomiólisis/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...